Dapagliflozin in patients with heart failure and reduced ejection fraction

New England Journal of Medicine

Volumn 381, Issue 21, 2019, Pages 1995-2008

  McMurray, J J V ^a   Solomon, S D ^b   Inzucchi, S E ^c   Kober, L ^d   Kosiborod, M N ^e   Martinez, F A ^f   Ponikowski, P ^g   Sabatine, M S ^h   Anand, I S ⁱ   Lohlavek, J B ^j   Bohm, M ^a   Chiang, C E ^b   Chopra, V K ^c   De Boer, R A ^k   Desai, A S ^l   Diez, M ^m   Drozdz, J ⁿ   Dukat, A ^o   Ge, J ^p   Howlett, J G ^q   Katova, T ^r   Kitakaze, M ^s   Ljungman, C E A ^t   Merkely, B ^d   Nicolau, J C ^u   O'Meara, E ^v   Petrie, M C ^a   Vinh, P N ^w   Schou, M ^d   Tereshchenko, S ^x   Verma, S ^ac   Held, C ^z   DeMets, D L ^aa   Docherty, K F ^a   Jhund, P S ^a   Bengtsson, O ^ab   Sjostrand, M ^y   Langkilde, A M ^f   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Rigshospitalet   (Denmark)

^e SAARLAND UNIVERSITY   (Germany)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g UNIVERSITY OF CÓRDOBA   (Spain)

^h INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

ⁱ WROCLAW MEDICAL UNIVERSITY   (Poland)

^j MEDICAL UNIVERSITY OF LODZ   (Poland)

^k UNIVERSITY OF MINNESOTA   (United States)

^l CHARLES UNIVERSITY   (Czech Republic)

^m NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁿ Medanta ^*  (India)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p Physics and Informatics   (Slovakia)

^q FUDAN UNIVERSITY   (China)

^r UNIVERSITY OF CALGARY   (Canada)

^s MONTREAL HEART INSTITUTE   (Canada)

^t National Cardiology Hospital   (Bulgaria)

^u NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^v UNIVERSITY OF GOTHENBURG   (Sweden)

^w UPPSALA UNIVERSITY   (Sweden)

^x SEMMELWEIS UNIVERSITY   (Hungary)

^y UNIVERSITY OF SÃO PAULO   (Brazil)

^z Tan Tao University   (Viet Nam)

^aa INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^ab UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^ac ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DAPAGLIFLOZIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PLACEBO; SACUBITRIL PLUS VALSARTAN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; CARDIOVASCULAR AGENT; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EVENT; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECT; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85073118508     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1911303     Document Type: Article

References (20)

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-57.
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-57.
4. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-306.
5. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: Proposal of a novel mechanism of action. JAMA Cardiol 2017; 2: 1025-9.
6. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia 2018; 61: 2108-17.
7. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation 2018; 138: 1904-7.
8. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: Potential mechanisms, clinical applications, summary of clinical trials. Circulation 2017; 136: 1643-58.
9. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue lowgrade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018; 44: 457-64.
10. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-34.
11. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-9.
12. McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019; 21: 665-75.
13. McMurray JJV, DeMets DL, Inzucchi SE, et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: Baseline characteristics. Eur J Heart Fail 2019 July 15 (Epub ahead of print).
14. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol 2000; 35: 1245-55.
15. Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation 2018; 137: 961-72.
16. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J R Stat Soc Series B Stat Methodol 2000; 62: 711-30.
17. Wang D, Pocock S. A win ratio approach to comparing continuous nonnormal outcomes in clinical trials. Pharm Stat 2016; 15: 238-45.
18. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
19. McMurray JJ. Neprilysin inhibition to treat heart failure: A tale of science, serendipity, second chances. Eur J Heart Fail 2015; 17: 242-7.
20. Packer M. Reconceptualization of the molecular mechanism by which sodiumglucose cotransporter 2 inhibitors reduce the risk of heart failure events. Circulation 2019; 140: 443-5.